Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 901–1,000 of 1,003
Accelerating drug development for Alzheimer's disease through the use of data standards
Neville, J., Kopko, S., Romero, K., Corrigan, B., Stafford, B., LeRoy, E. C., Broadbent, S., Cisneroz, M., Wilson, E., Reiman, E. M., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.006 · Cited by 16
“population for most therapeutic trials that had been carried out historically [18].”
BackgroundPowell, T. P. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0868-0 · Cited by 19
van Gastel, J., Hendrickx, J. O., Leysen, H., Martin, B., Veenker, L., Beuning, S., Coppens, V., Morrens, M., & Maudsley, S. R. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_39 · Cited by 16
The need for better AD animal models
Medina, M., & Ávila, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00227 · Cited by 19
“In particular, drug development success rate has been staggering low with many small molecules and immunotherapies failing to show efficacy or superiority over placebo in late clinical trials (Cummings et al., 2014).”
BackgroundDalvi, T., Dewangan, B., Agarwal, G., Suchita, D. S., Jain, A. K., Srivastava, A., & Sahu, B. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127999 · Cited by 16
Habiba, U., Ozawa, M., CHAMBERS, J. K., Uchida, K., Descallar, J., Nakayama, H., Summers, B. A., Morley, J. W., & Tayebi, M. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210035 · Cited by 22
“Significantly, favorable immunotherapeutic outcomes using AD transgenic animal models [7, 8] have failed to translate into effective human therapy, which raises serious doubts as to the validity of these amyloid-focused experimental models.”
BackgroundNazari, M., Vajed-Samiei, T., Torabi, N., Fahanik‐Babaei, J., Saghiri, R., Khodagholi, F., & Eliassi, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02681-7 · Cited by 18
“To date, antibody therapy, vaccines, and pharmacological approaches have not successfully produced effective therapies for the disease [2, 3].”
BackgroundDiStefano, M. J., Alexander, G. C., Polsky, D. E., & Anderson, G. F. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17692 · Cited by 15
Bennett, E. E., Song, Z., Lynch, K. M., Liu, C., Stapp, E. K., Xu, X., Park, E. S., Ying, Q., Smith, R. L., Stewart, J. D., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108200 · Cited by 16
“Identifying modifiable risk factors for Alzheimer ’ s disease (AD) remains a top priority for dementia-related research, as the failure rate for clinical trials of AD treatments remains staggeringly high (Cummings et al., 2014).”
Dementia prevention: the Mendelian randomisation perspective
Anderson, E. L., Davies, N. M., Korologou‐Linden, R., & Kivimäki, M. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-332293 · Cited by 25
Developing diagnostic biomarkers for Alzheimer's disease based on histone lactylation-related gene
Guo, S., Zhu, W., Bian, Y., Li, Z., Zheng, H., Li, W., Yang, Y., Ji, X., & Zhang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37807 · Cited by 17
“The United States Food and Drug Administration has approved five pharmacological treatments for AD: donepezil, rivastigmine, galantamine, memantine, and a memantine-donepezil combination [4].”
BackgroundJin, K., Lv, Z., Pang, X., Zhu, C., Liu, R., Wei, Y., & Pang, C.-Y. (2024) · Aging advances. · doi:10.4103/agingadvances.agingadv-d-24-00004 · Cited by 16
Singh, P. K., Kawasaki, M., Berk-Rauch, H., Nishida, G., Yamasaki, T., Foley, M. A., Norris, E. H., Strickland, S., Aso, K., & Ahn, H. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01214 · Cited by 15
Preventive approach for overcoming dementia
Lee, H., Kim, D.-W., Lee, W., Kim, H. Y., & Kim, Y. S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01168-3 · Cited by 16
Chiarini, A., Armato, U., Hu, P., & Prà, I. D. (2020) · Cells · doi:10.3390/cells9061386 · Cited by 17
“These hard facts underscore the persistently failed translation of promising anti-AD drugs from AD-model animals to human AD patients [6,16,17].”
BackgroundBanks, S. J., Qiu, Y., Fan, C. C., Dale, A. M., Zou, J., Askew, B., Feldman, H., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12071 · Cited by 18
Delineating the Role of Mitophagy Inducers for Alzheimer Disease Patients
Wang, W., Han, R., He, H., Wang, Z., Luan, X., Li, J., Feng, L., Chen, S., Aman, Y., & Xie, C. (2021) · Aging and Disease · doi:10.14336/ad.2020.0913 · Cited by 15
“Over the past 15 years over 250 drug candidates have been attempted for potential treatment AD, largely targeting the proteins p-tau or Aβ, but all have been unsuccessful [12].”
BackgroundKondak, C., Riedel, G., Harrington, C. R., Wischik, C. M., & Klein, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15553 · Cited by 16
Wakeman, D. R., Weed, M. R., Perez, S. E., Cline, E. N., Viola, K. L., Wilcox, K. C., Moddrelle, D. S., Nisbett, E. Z., Kurian, A., Bell, A., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12800 · Cited by 19
“Disappointingly, the past few years have seen a series of failures of Phase 2 and Phase 3 clinical trials [3,4].”
BackgroundKnowledge and Attitudes in Alzheimer’s Disease in a Cohort of Older African Americans and Caucasians
Howell, J. C., Soyinka, O., Parker, M., Jarrett, T. L., Roberts, D. L., Dorbin, C. D., & Hu, W. T. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515619037 · Cited by 18
Rodent Models for Alzheimer’s Disease in Drug Discovery
Barrett, J. E., & McGonigle, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00012-x · Cited by 16
Multitarget Anti-Alzheimer Hybrid Compounds
Muñoz‐Torrero, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101011-2.00006-4 · Cited by 19
A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment
Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.05.011 · Cited by 17
Marmosets as a translational aging model—Introduction
Tardif, S. D. (2019) · American Journal of Primatology · doi:10.1002/ajp.22912 · Cited by 15
Singh, P. K., Badimon, A., Chen, Z., Strickland, S., & Norris, E. H. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12504 · Cited by 20
Should we move dementia research funding from a cure to its care?
Wong, G. H. Y., & Knapp, M. R. J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1735364 · Cited by 21
Oxtoby, N. P., Shand, C., Cash, D. M., Alexander, D. C., & Barkhof, F. (2022) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2022.660581 · Cited by 14
“Despite decades of research and clinical trials of potential therapies (1), no trials have been able to prove disease-modifying efficacy (2, 3, 4, 5, 6, 7).”
BackgroundForlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Sun, Y., Liu, S., Chen, L., Zhou, Z., Yin, X., Shi, Y., Li, H., Li, J., Lü, Y., Jiang, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz9283 · Cited by 20
“Despite extensive global efforts and approximately 200 clinical trials aimed at developing therapeutics for AD, nearly all have failed, with an alarmingly high failure rate approaching 99.6 % ( 4 , 5 ).”
InfluentialPeptidotriazolamers Inhibit Aβ(1–42) Oligomerization and Cross a Blood‐Brain‐Barrier Model
Tonali, N., Hericks, L., Schröder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Joncour, V. L., Laakkonen, P., Marion, A., Ongeri, S., et al. (2021) · ChemPlusChem · doi:10.1002/cplu.202000814 · Cited by 16
Kitaigorodsky, M., Crocco, E., Curiel, R. E., Leal, G. M. A., Zheng, D. D., Eustache, M. K., Greig‐Custo, M. T., Barker, W., Duara, R., & Loewenstein, D. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12192 · Cited by 23
“5; (4) impaired delayed recall (ie, scored 1.”
BackgroundMethodHuman iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging
Chao, C., Shen, P.-W., Tzeng, T., Kung, H., Tsai, T., & Wong, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9111635 · Cited by 15
Chen, H., Qiao, J., Wang, T., Shao, Z., Huang, S., & Zeng, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.680104 · Cited by 15
“For example, given few effective drugs are available for these diseases (Al-Chalabi and Hardiman, 2013), these identified metabolites may be prioritized as candidate therapeutic targets for NDDs (Cummings et al., 2014; Lu et al., 2016), especially 2-methoxyacetaminophen sulfate for ALS or FTD.”
BackgroundSekimitsu, S., Shweikh, Y., Shareef, S., Zhao, Y., Elze, T., Segrè, A. V., Wiggs, J. L., & Zebardast, N. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-322762 · Cited by 18
Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients
Leitner, D., Kanshin, E., Faustin, A., Thierry, M., Friedman, D. J., Devore, S., Ueberheide, B. M., Devinsky, O., & Wısnıewskı, T. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1221775 · Cited by 21
Bax inhibitor 1 is a γ-secretase–independent presenilin-binding protein
Wu, S., Song, W., Wong, C. C. L., & Shi, Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810870116 · Cited by 17
“However, none of the compounds that alter Aβ peptide production through modulation of γ-secretase has produced clear clinical efficacy (8).”
BackgroundA disease-modifying treatment for Alzheimer’s disease: focus on the trans-sulfuration pathway
Berry, T. M., Hamza, E. A., & Moustafa, A. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0076 · Cited by 15
Moniruzzaman, M., Kadota, A., Akash, M. S., Pruitt, P. J., Miura, K., Albin, R. L., & Dodge, H. H. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12109 · Cited by 18
Lim, J. Y., Lee, J. E., Park, S. A., Park, S., Yon, J.-M., Park, J.-A., Jeun, S., Kim, S. J., Lee, H. J., Kim, S. W., et al. (2022) · Cells · doi:10.3390/cells11061029 · Cited by 17
Cuberas‐Borrós, G., Roca, I., Castell‐Conesa, J., Núñez, L., Boada, M., López, O. L., Grifols, C., Barceló, M., Pareto, D., & Páez, A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05915-5 · Cited by 14
Therapeutic potential of extracellular vesicles in neurodegenerative disorders
Roudi, S., Rädler, J., & Andaloussi, S. E. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00017-5 · Cited by 15
Emerging Nanotechnology for the Treatment of Alzheimer’s Disease
Singh, A., Ansari, V. A., Mahmood, T., Ahsan, F., Wasim, R., Maheshwari, S., Shariq, M., Parveen, S., & Shamim, A. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230501232815 · Cited by 14
Can we influence the epidemiology of dementia? Perspectives from population-based studies
Birdi, R., Stephan, B. C. M., Robinson, L. A., & Davis, D. H. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133244 · Cited by 15
Ethical considerations and challenges in first-in-human research
Koonrungsesomboon, N., Laothavorn, J., & Karbwang, J. (2016) · Translational research · doi:10.1016/j.trsl.2016.05.006 · Cited by 22
Young, S. C. (2018) · Molecules · doi:10.3390/molecules23020296 · Cited by 14
“6% of AD drugs that entered clinical trials failed, which is a higher rate of failure than either oncology or cardiovascular drugs [6,7].”
BackgroundAssessing drug response in engineered brain microenvironments
Tate, K. M., & Munson, J. M. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.04.027 · Cited by 15
“Between the years of 2002 and 2012, there were 413 Alzheimer’s disease related clinical trials in the United States (Cummings et al., 2014).”
BackgroundAhlgrim, N. S., Garza, K. M., Hoffman, C. A., & Rommelfanger, K. S. (2019) · eNeuro · doi:10.1523/eneuro.0439-18.2019 · Cited by 19
“In recent years, preclinical trials have commanded more of the industry’s effort, given the poor success rate of pharmaceutical trials in clinical interventions (Cummings et al., 2014; Hung and Fu, 2017).”
BackgroundКонвергенция концепций патогенеза болезни Альцгеймера
Kozin, S. A., & Makarov, A. А. (2019) · Molecular Biology · doi:10.1134/s0026898419060107 · Cited by 14
Teo, E., Lim, J., Fong, S., Larbi, A., Wright, G. D., Tolwinski, N. S., & Gruber, J. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.12.002 · Cited by 22
Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 16
“…2004, 2011; Liang et al., 2007; Berchtold et al., 2008; Bronner et al., 2009; Williams et al., 2009; Nunez-Iglesias et al., 2010; Tan et al., 2010; Durrenberger et al., 2012; Antonell et al., 2013; Fischer et al., 2013; Janssen et al., 2013; Miller et al., 2013; Zhang et al., 2013; Hokama et al.,…”
Bednarz, K., & Siuda, J. S. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0056 · Cited by 15
“Memantine exerts neuroprotective activity by NMDA receptor antagonism [13, 53].”
BackgroundReply to: APP gene copy number changes reflect exogenous contamination
Lee, M.-H., Liu, C. S., Zhu, Y., Kaeser, G. E., Rivera, R. R., Romanow, W. J., Kihara, Y., & Chun, J. J. M. (2020) · Nature · doi:10.1038/s41586-020-2523-2 · Cited by 14
Potential Role for Herpesviruses in Alzheimer’s Disease
Duggan, M. R., Torkzaban, B., Ahooyi, T. M., & Khalili, K. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200814 · Cited by 13
“Meanwhile, the drug development process is largely unsuccessful, with the vast majority of preclinical results failing to translate into clinical benefits [26, 27].”
Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13
A Genetically Heterogeneous Rat Model with Divergent Mitochondrial Genomes
Sathiaseelan, R., Ahn, B., Stout, M. B., Logan, S., Wanagat, J., Nguyen, H. V. M., Hord, N. G., Vandiver, A. R., Selvarani, R., Ranjit, R., et al. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad056 · Cited by 16
Wang, Y., Wang, Z., Guo, S., Li, Q., Kong, Y., Sui, A., Ma, J., Li, L., Zhao, J., & Li, S. (2024) · Antioxidants · doi:10.3390/antiox13060628 · Cited by 14
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 18
“The first A (cid:2) -targeting monoclonal antibody created for AD was bapineuzumab and that due to multiple reasons including but not limited to, a lack of efficacy and safety issues, its clinical trials did not succeed [47].”
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 20
“Addressing these concerns will help to improve the success rate in AD drug development, particularly in passive immunotherapy trials, which has been the most successful disease-modifying approach 49,50 .”
BackgroundValls-Comamala, V., Guivernau, B., Bonet, J., Puig, M., Perálvarez‐Marín, A., Palomer, E., Fernàndez‐Busquets, X., Altafaj, X., Tajes, M., Puig‐Pijoan, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17074 · Cited by 16
“com/oncotarget for AD are cholinesterase inhibitors (tacrine, donezepil, galantamine, rivastigmine) and also, a NMDA receptor antagonists (memantine) [47].”
BackgroundNeurodegenerative Drug Discovery: Building on the Past, Looking to the Future
Bolognesi, M. L. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0087 · Cited by 13
Geerts, H., Gieschke, R., & Peck, R. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1501555 · Cited by 13
“4% [1], despite a substantial investment.”
den Broeck, L. V., Sierksma, A. S. R., Hansquine, P., Thonnard, D., Callaerts‐Vegh, Z., & D’Hooge, R. (2020) · Genes Brain & Behavior · doi:10.1111/gbb.12695 · Cited by 18
“During the last 15 years, most clinical trials in AD drug development unfortunately failed.(18,19) The relative lack of sensitive and clinically valid rodent tests might be one of the reasons for this limited translational result of preclinical AD research.”
BackgroundREDD1 Is Involved in Amyloid β-Induced Synaptic Dysfunction and Memory Impairment
Yi, J. H., Kwon, H., Cho, E., Jeon, J., Lee, J., Lee, Y. C., Cho, J. H., Jun, M., Moon, M., Ryu, J. H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249482 · Cited by 16
Chan, A. M., & Fletcher, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00286k · Cited by 13
JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model1
Dennison, J. L., Volmar, C., Modarresi, F., Ke, D., Wang, J., Gravel, E., Vignini-Hammond, S., Li, Z., Timmons, J. A., Lohse, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215370 · Cited by 13
Fernandes, A. M. A., Caldeira, C., Cunha, C., Ferreiro, E. B., Vaz, A. R., & Brites, D. M. T. O. (2022) · Cells · doi:10.3390/cells11010137 · Cited by 16
“Recently, the validity of such models has been questioned by the high failure rate of clinical trials of AD therapeutics (>99%) that were successful in preclinical trials using these models [3].”
BackgroundKumar, N., Gupta, P., & Bansal, S. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220314144219 · Cited by 16
Exploring the zinc-related transcriptional landscape in Alzheimer’s disease
Shippy, D. C., & Ulland, T. K. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.06.002 · Cited by 16
Tari, A. R., Berg, H. H., Videm, V., Bråthen, G., White, L. R., Røsbjørgen, R. N., Scheffler, K., Dalen, H., Holte, E., Haberg, A. K., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056964 · Cited by 16
Bioluminescence Imaging with Functional Amyloid Reservoirs in Alzheimer’s Disease Models
Yang, J., Ding, W., Zhu, B., Zhen, S. Y., Kuang, S., Yang, J., Zhang, C. M., Wang, P., Yang, F., Yang, L., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02358 · Cited by 13
Chen, B., Li, W., Wang, G., Li, G., Liu, J.-Q., Zheng, J., Wang, Q., Li, H., Dai, S., & Huang, J. (2018) · PeerJ · doi:10.7717/peerj.4756 · Cited by 13
“However, there is currently no 71 method for reversing or curing AD (Cummings et al. 2014; Peng et al. 2016), and Tacrine has 72 been discontinued in the United States market.”
MethodAllix, F., Gembus, V., Coquet, L., Hubert‐Roux, M., Chan, P., Truong, L., Sebban, M., Coadou, G., Oulyadi, H., Papamicaël, C. A., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b02121 · Cited by 14
Developing Trojan horses to induce, diagnose and suppress Alzheimer’s pathology
Aziz, A. A., & Amtul, Z. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104471 · Cited by 15
Tan, S. Z. K., Neoh, J., Lawrence, A. J., Wu, E. X., & Lim, L. W. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00913-7 · Cited by 14
Repeated performance of spatial memory tasks ameliorates cognitive decline in APP/PS1 mice
Lonnemann, N., Körte, M., & Hosseini, S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114218 · Cited by 12
Sun, H., Gao, X., Niu, J., Chen, P., He, S., Xu, S., & Ge, J. (2024) · eneuro · doi:10.1523/eneuro.0310-24.2024 · Cited by 12
“However, only fi ve treatment options are currently approved in the United States to address the cognitive symptoms of AD, with the most recent approval being memantine over a decade ago (Cummings et al., 2014).”
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
Ilango, S. D., Leary, C. S., Ritchie, E., Semmens, E. O., Park, C., Fitzpatrick, A. L., Kaufman, J. D., & Hajat, A. (2023) · Environmental Epidemiology · doi:10.1097/ee9.0000000000000250 · Cited by 14
“We selected the following measures of social environment: (1) arts, entertainment, and recreational organizations; (2) eating and drinking places; (3) religious, civic, and social organizations; and (4) social services; these reflect opportunities of social engagement that have been previously linked to measures of co…”
MethodPutative pathological mechanisms of late-life depression and Alzheimer’s disease
Hasan, S. M. N., Clarke, C., Strand, T., & Bambico, F. R. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148423 · Cited by 14
A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
McNett, S., Vyshedskiy, A., Savchenko, A., Durakovic, D., Heredia, G., Cahn, B. R., & Kogan, M. (2023) · Healthcare · doi:10.3390/healthcare11142040 · Cited by 12
“Despite the devastating touch this disease has on individuals, families, the healthcare system and society, effective treatment options are severely limited [3].”
BackgroundHuman iPSC-derived retinal organoids develop robust Alzheimer’s disease neuropathology
James, E., Vielle, A., Cusato, K., Li, H., Lee, B., Parween, S., Howell, A., Johnson, N. R., Chial, H. J., Potter, H., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1340448 · Cited by 13
“Unfortunately to date, there are no therapies that can stop or reverse the progression of AD (Cummings et al., 2014; Kusne et al., 2017).”
BackgroundHerold, F., Theobald, P., Gronwald, T., Kaushal, N., Zou, L., de Bruin, E. D., Bherer, L., & Müller, N. G. (2024) · JMIR Aging · doi:10.2196/56433 · Cited by 17
“This assumption is reinforced by the fact that the effectiveness of pharmacological interventions to treat dementia is limited [10,11].”
BackgroundKokkali, M., Karali, K., Thanou, E., Παπαδοπούλου, Μ., Zota, I., Tsimpolis, A., Efstathopoulos, P., Calogeropoulou, T., Li, K. W., Sidiropoulou, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02833-w · Cited by 15
“The majority of drugs tested in clinical trials have been immunotherapy-based monoclonal antibodies (mAbs) targeting a single protein, mainly amyloid, with a failure rate approaching 100% [20].”
Alves, R. L., Gonçalves, A., Voytyuk, I., & Harrison, D. C. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115234 · Cited by 11
Huang, Y., & Alsabbagh, M. W. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.622 · Cited by 17
Salisbury, D. L., Plocher, T., & Yu, F. (2021) · Trials · doi:10.1186/s13063-020-04950-7 · Cited by 12
“Interventions at later clinical phases of AD have been ineffective or shown only modest benefits [3].”
BackgroundNanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation
Ribarič, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031102 · Cited by 13
Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications
Li, T., Hou, X., Yu, Q., Duan, X., Yan, P., Zhu, H., Xie, Z., & Zhang, H. (2021) · Nano Research · doi:10.1007/s12274-021-3865-2 · Cited by 12
Sanderson‐Cimino, M. E., Elman, J. A., Tu, X. M., Gross, A. L., Panizzon, M. S., Gustavson, D. E., Bondi, M. W., Edmonds, E. C., Eppig, J. S., Franz, C. E., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.847315 · Cited by 14
Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20106 · Cited by 13
Poon, C. H., Liu, Y., Pak, S., Zhao, R. C., Aquili, L., Tipoe, G. L., Leung, G., Chan, Y., Yang, S., Fung, M., et al. (2022) · Aging and Disease · doi:10.14336/ad.2022.0706 · Cited by 13
“The development of effective dementia treatments is challenging, as demonstrated by the frequent failure to validate the therapeutic effects of drug interventions in clinical trials [1, 2].”
BackgroundLeroy, V., Gana, W., Aïdoud, A., Nkodo, J., Balageas, A., Blanc, P., Bomia, D., Debacq, C., & Fougère, B. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01227-4 · Cited by 12
“However, the failure rate for therapeutic trials in AD is particularly high: 99.6% in 2014, according to Cummings et al. [9].”
BackgroundInfluentialAβ Oligomer Dissociation Is Catalyzed by Fibril Surfaces
Dear, A. J., Thacker, D., Wennmalm, S., Ortigosa-Pascual, L., Andrzejewska, E. A., Meisl, G., Linse, S. S., & Knowles, T. P. J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00127 · Cited by 17
Szałaj, N., Bajda, M., Dudek, K., Brus, B., Gobec, S., & Malawska, B. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201500117 · Cited by 12
Godwin, B., & Poland, F. M. (2015) · Quality in Ageing and Older Adults · doi:10.1108/qaoa-08-2015-0038 · Cited by 12
Snir, J. A., Suchý, M., Lawrence, K. S., Hudson, R. H. E., Pasternak, S., & Bartha, R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150123 · Cited by 14
“This problem has taken on urgency, as several promising clinical trials may have failed, because treatment was initiated too late in the disease, when irreversible synaptic and neuronal loss had already occurred [7–11].”
BackgroundModulators of Amyloid β-Protein (Aβ) Self-Assembly
Rahimi, F., Li, H. J., Sinha, S., & Bitan, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00006-x · Cited by 15
“safety issues, decreasing hope for a breakthrough therapy (Cummings et al., 2014; Doody et al., 2014; Salloway et al., 2014).”
BackgroundAnticoagulants inhibit proteolytic clearance of plasma amyloid beta
Yang, L., Bhattacharya, A., Li, Y., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23718 · Cited by 12
“However, in clinical trials Aβ-targeted therapies have been ineffective [6, 7].”
BackgroundHascup, K. N., Britz, J., Findley, C. A., Tischkau, S. A., & Hascup, E. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181231 · Cited by 14
“Current pharmacotherapy options target cholinesterase inhibitors, to increase acetylcholine levels, and N-methyl-D-aspartate (NMDA) receptor antagonism, to prevent glutamate mediated excitotoxicity [3, 4].”
CDEK: Clinical Drug Experience Knowledgebase
Griesenauer, R. H., Schillebeeckx, C., & Kinch, M. S. (2019) · Database · doi:10.1093/database/baz087 · Cited by 12
“gov to extract insights on investigational pipelines for specific clinical indications and specialties (Alzheimer’s (14) and Nephrology (15), for example).”
Background
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
